Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
Recruiting · NCT06668493 · Registry updated 2026-09-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis | Low-grade Upper Tract Urothelial Carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-09-15 | NCT06668493 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ferring Pharmaceuticals | 18 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Baylor College of Medicine (Houston) | Houston | United States | 1 |
| Hospital Tenon, Sorbone University | Paris | France | 1 |
| Mayo Clinic | Jacksonville | United States | 122 |
| Mayo Clinic - Rochester Minnesota | Rochester | United States | 2 |
| Mayo Clinic - Scottsdale Arizona | Scottsdale | United States | 1 |
| MD Anderson Cancer Center - Genitourinary (GU) Cancer Center | Houston | United States | 1 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Providence Saint John's Cancer Institute | Santa Monica | United States | 5 |
| University of Pennsylvania - Perelman Center for Advanced Medicine - Penn Urology | Philadelphia | United States | 3 |